Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL237 plus serplulimab for PTEN-deficient or PTEN-low advanced solid tumors
CTR20252781Phase 2Active
- Sponsor
- Convalife Pharmaceutical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CVL237, serplulimab in Nonhematologic neoplasms, gastric cancer (GC), endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer, sponsored by Convalife Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
CVL237serplulimab
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)endometrial cancer (EC)Cervical Cancer (CC)ovarian cancer
Beyond the preview
Go deeper on CTR20252781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252781.